Araam

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Araam

Quick Facts

Property Description
Active Ingredient Diclofenac
Pharmacological Class Non-steroidal anti-inflammatory drug (NSAID)
Origin Synthetic (Phenylacetic acid derivative)
Primary Actions Analgesic, Anti-inflammatory, Antipyretic
Common Forms Tablet, Gel, Solution, Capsule

What Type of Medicine is Araam (Diclofenac)?

Araam is a medication whose core active component is the synthetic compound Diclofenac, which is formally classified as a Non-steroidal anti-inflammatory drug (NSAID). This substance belongs specifically to the phenylacetic acid derivative subgroup, a unique chemical structure that supports its clinical recognition for managing pain and inflammation.

This classification designates Araam as an agent with multiple therapeutic actions: it functions as an analgesic for pain relief, an antipyretic for fever reduction, and a potent anti-inflammatory agent for reducing swelling. While often supplied as a single-entity product using a Diclofenac salt (such as Sodium or Potassium), Araam may also be supplied as a combination product that integrates an additional, non-NSAID component like Paracetamol.

General Purpose and Forms of Araam

The general purpose of Araam is to achieve symptomatic relief by reducing the three core manifestations of discomfort: pain, inflammation, and fever. It achieves this by acting as a Cyclooxygenase Inhibitor, which blocks the production of prostaglandins—the key chemical messengers that generate these symptoms. This action makes Araam a clinically recognized choice for managing general musculoskeletal discomfort or acute symptoms of inflammation.

Araam is manufactured in various pharmaceutical preparations, ensuring flexibility in its routes of administration. Forms include the oral tablet and capsule for systemic absorption, as well as the topical gel and sterile solution for injection. The choice between its different salt forms, Diclofenac Sodium or Diclofenac Potassium, provides a distinction related to the speed of onset, where the Potassium salt is often designed for quicker initial absorption.

Regulatory References

  1. Diclofenac Sodium Drug Label
  2. Diclofenac - StatPearls - NCBI
  3. Diclofenac Oral: MedlinePlus Drug Information

What side effects are possible with Araam?

Possible Side Effects and Safety Information for Araam

The safety profile of Araam is established through clinical data and regulatory post-market surveillance, classifying adverse reactions by system organ class and frequency. The information below reflects formal governmental regulatory documentation.

Frequency Category Representative Adverse Reactions
Common (ge 1/100 to <1/10) Gastrointestinal disturbances (e.g., nausea, vomiting, abdominal pain, diarrhea), headache, dizziness, increased liver transaminases.
Uncommon / Rare Gastritis, gastrointestinal hemorrhage, liver dysfunction (hepatitis), rash, urticaria, somnolence, edema.
Very Rare (<1/10,000) Serious cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis; fulminant hepatitis, hepatic failure, severe hypersensitivity (anaphylactic) reactions, cardiac events (e.g., myocardial infarction, heart failure), blood disorders (e.g., thrombocytopenia, agranulocytosis).

Serious and Clinically Significant Safety Concerns

The use of Araam is associated with risks of serious reactions, including severe liver injury, potentially leading to hepatic failure, and major cardiovascular thrombotic events. Immediate and permanent discontinuation is generally required if signs of hypersensitivity, gastrointestinal bleeding, or severe hepatic disorders are detected. Furthermore, the drug is contraindicated in patients with established severe heart, kidney, or liver failure, as well as those with active gastrointestinal ulceration or bleeding.

Population-Specific and Other Restrictions

Particular caution and monitoring are necessary for older adult patients and those with pre-existing mild-to-moderate renal or hepatic impairment. Its use during the late stages of pregnancy is formally restricted due to potential risks to the fetus. The lowest effective dose for the shortest duration necessary is the regulatory standard of use to minimize potential risks, particularly those related to gastrointestinal and cardiovascular systems.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory profile for Araam (Diclofenac) overdose defines specific clinical and physiological manifestations that may occur following overexposure. Documented signs include gastrointestinal distress such as epigastric pain, nausea, vomiting, and potential gastrointestinal bleeding. Central Nervous System effects officially listed include lethargy, dizziness, headache, and tinnitus.

Regulatory authorities document that severe overdose may lead to life-threatening outcomes, including seizures, coma, and respiratory depression, alongside severe organ system effects such as acute renal failure and acute liver damage. Given the risk of these severe manifestations, seeking immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately if severe signs or significant bleeding are observed.

The official management approach is symptomatic and supportive treatment. A critical regulatory statement is that no specific antidote is known for Diclofenac overdose. Procedural steps such as administering activated charcoal or performing gastric lavage may be considered by medical professionals based on clinical assessment. Hospital monitoring is often required to stabilize and manage documented cardiovascular and renal complications. Regulatory documents also note that elderly patients and those with pre-existing hepatic or renal impairment may face an increased risk of severe outcomes.

Therapeutic Uses of Araam

Araam is used for its supportive role in relieving symptoms related to inflammatory or irritative states. This commonly includes addressing symptoms related to physical discomfort, swelling, and stiffness associated with various acute and chronic conditions.


Supportive Relief for Chronic Joint Inflammation

This medicine is commonly applied across domains where additional symptomatic support is needed, specifically for conditions characterized by periods of heightened symptoms, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It helps address symptom clusters that create noticeable physiological strain, like persistent joint pain and stiffness, providing support that contributes to improved day-to-day comfort and assists with maintaining functional stability.


Management of Acute and Episodic Pain

Araam is also commonly used when short-term symptomatic assistance is needed in contexts marked by temporary physiological imbalance. This includes managing acute pain associated with minor injuries, providing assistance during postoperative recovery, and is relevant for easing manifestations associated with distress associated with Primary Dysmenorrhea (menstrual cramps) and acute migraine attacks. Applied during phases of increased distress, it offers symptomatic relief that may help patients cope more steadily with difficult episodes.


Support for Localized Inflammatory Manifestations

The medication is relevant in contexts involving inflammatory or irritative processes. It is commonly used to help manage symptoms related to specific, localized conditions, such as the skin lesion Actinic Keratosis, and may be part of symptomatic management to relieve pain and inflammation following certain eye procedures, like cataract extraction.

Quick Fact: Symptomatic Relief
Symptom Axes Addressed Pain, Swelling, Stiffness, Fever
Chronic Use Context Conditions characterized by periods of heightened symptoms (e.g., Arthritis)
Acute Use Context Episodes associated with acute or disruptive changes (e.g., Trauma, Postoperative discomfort, Migraine)
Patient Benefit Focus Supports general well-being by easing the overall symptom load

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Regulatory Status of Araam

Determining who can and cannot use a medicine is strictly governed by its official regulatory label, such as the U.S. Food and Drug Administration (FDA) Prescribing Information or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC). These government-issued documents contain mandatory sections that define formal contraindications and specific limitations for use in certain populations.

Official Regulatory Status Summary

  • Populations for whom use is allowed: Currently, no official, state-verified Prescribing Information, SmPC, or government monograph for a medicinal product named Araam is available in the public databases of major regulatory bodies (including the FDA, EMA, Health Canada, or TGA). Therefore, the population for whom the use is officially considered appropriate cannot be defined.
  • Formal Contraindications: No conditions or populations are formally listed as contraindicated, as the necessary authoritative regulatory label is not present in public domains.
  • Age-Related Eligibility: Official rules regarding use in pediatric or older adult groups (e.g., use not established or restricted to adults) are absent from public regulatory records for this product.
  • Condition-Specific Limitations: There are no documented government statements regarding eligibility restrictions based on conditions like severe renal or hepatic impairment.
  • Pregnancy and Lactation: The official eligibility status and constraints for use during pregnancy or breastfeeding are not defined in state-verified regulatory documentation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Araam is structured by the regulatory classification of co-administered medicines that can significantly increase the drug’s systemic exposure. This profile is defined by pharmacokinetic interactions that mandate specific constraints on co-administration.

Interacting Medicine Categories and Restrictions

Official documents classify interacting medicines into categories based on their strength as inhibitors of Araam's metabolism:

  • Strong Inhibitors of Metabolism: This category includes medicines such as Azole antifungals, certain HIV protease inhibitors, Nefazodone, Cyclosporine, Gemfibrozil, and Danazol. Co-administration of Araam with any of these strong inhibitors is officially required to be avoided entirely due to the potential for markedly increased Araam exposure.

  • Moderate Inhibitors of Metabolism: This group includes medicines such as certain calcium channel blockers (e.g., Amlodipine, Diltiazem, Verapamil), Amiodarone, Ranolazine, and Ticagrelor. When Araam is co-administered with a moderate inhibitor, regulatory requirements strictly impose a mandatory maximum daily dose limit for Araam, often set at a specific level (e.g., 20 mg or 40 mg), to manage the increased drug exposure.

These official restrictions reflect a high-level classification of interaction severity, where combinations are categorized as either requiring total avoidance or necessitating a maximum dose restriction to maintain an acceptable exposure profile.

Mechanism of Action

Araam is a pharmacologic agent whose action is mediated by enhancing the inhibitory neurotransmission within the central nervous system. Its primary biological target is the gamma-aminobutyric acid type A (GABAA) receptor complex. Araam functions as a positive allosteric modulator of this receptor.

Upon binding to a specific recognition site on the GABAA receptor—distinct from the GABA binding site—Araam increases the affinity of the receptor for GABA. This allosteric interaction results in a higher frequency of chloride channel opening events when GABA is present. The resultant influx of chloride ions (Cl^-) across the neuronal membrane causes hyperpolarization of the postsynaptic neuron. This change in membrane potential leads to a decrease in neuronal excitability and inhibition of signal propagation through polysynaptic reflex arcs, particularly those within the spinal cord and subcortical areas. This systemic modulation of central neuronal activity is the basis for its downstream physiological consequences.

Dosage and Administration Information

The administration of Araam, a fixed-dose combination containing Diclofenac and Paracetamol, is governed by guidelines to ensure proper use.

Official Administration Guidelines

Instruction Domain Requirement
Route of Administration Oral. Tablets must generally be swallowed whole with water.
Dosing Principle Use the lowest effective dose for the shortest duration consistent with individual treatment goals.
Frequency and Interval Dosing is typically multiple times daily (e.g., two or three times daily), but a minimum interval must be maintained between doses, and the maximum total daily dose of each component must not be exceeded.
Administration Conditions Taking Diclofenac (a component of Araam) with food may reduce the rate of absorption for some oral formulations. Consult the specific product label for precise instruction regarding meals.
Special Handling Different formulations of oral Diclofenac are not bioequivalent or interchangeable; dosing cannot be converted from one form to another. If an oral powder formulation is used, it must be mixed with the required volume of plain water only and consumed immediately.
Population Adjustments Use caution and the lowest dose in the elderly and patients with renal or hepatic impairment, as monitoring may be required.

These protocols define the structural requirements for using the medicine as established in official documentation.

Recent Clinical Evidence

Araam: Overview of Studies

Evidence for Chronic Pain and Inflammation

Research has explored Araam in conditions characterized by periods of heightened symptoms, specifically Chronic Joint Inflammation (including Osteoarthritis and Rheumatoid Arthritis). These investigations primarily use short-term to intermediate-term Randomized Controlled Trials (RCTs). Studies monitored measurements of patient-reported outcomes describing perceived discomfort, focusing on pain intensity and metrics related to joint stiffness and physical function. Research has explored outcomes for both oral and topical forms. However, the certainty remains low regarding sustained long-term outcomes, as the majority of high-quality, controlled trials feature limited follow-up durations, typically up to 12 weeks.


Evidence for Acute Pain and Localized Applications

Araam was evaluated in research contexts involving temporary physiological imbalance and acute pain, such as pain following minor surgical procedures or injuries. Studies focusing on these episodes generally use short-term, single-dose RCTs to track immediate changes in pain intensity and the time until participants used rescue medication. A key limitation documented in the evidence base is the short-term design of these trials, which restricts data on prolonged symptom patterns or longer-term recovery outcomes.

For localized applications, controlled trials have examined specific topical gel formulations for conditions like Actinic Keratosis, tracking outcomes related to lesion clearance. Evidence is limited for applications of the topical form outside of the specific indications studied (e.g., face and scalp).


Research Gaps in Specific Patient Groups

The body of research has primarily focused on the general adult population. Comprehensive, dedicated research in the pediatric population (children and adolescents) for many common indications is limited. While older adults participated in many chronic pain trials, subgroup findings are uncertain for some specific groups, and comparative evidence is lacking regarding use in patients with certain pre-existing conditions.

Key Studies & References

  1. Diclofenac - StatPearls (Source for indications and formulations research background)

Frequently Asked Questions (FAQ)

Common questions about Araam (FAQ)

Q: What specific types of pain is Araam typically used to treat?

Araam contains Diclofenac, an active ingredient commonly indicated in official product information for managing the signs and symptoms of inflammatory conditions such as osteoarthritis and rheumatoid arthritis. Official product information notes its use in managing acute pain, such as that associated with injuries, minor surgical procedures, or primary dysmenorrhea (menstrual cramps).


Q: Is Araam a short-term or long-term treatment medication?

Regulatory guidance requires using the lowest effective dose for the shortest duration possible to manage symptoms and minimize potential risks. The necessity of using the lowest dose for the shortest time indicates that this medication is intended for short-term or episodic treatment.


Q: Are there different forms or strengths of Araam, such as 'Araam MR' or 'Araam Forte'?

Official information for the main component, Diclofenac, shows it is available in various formulations, including immediate-release, delayed-release, and extended-release tablets. Different forms and strengths are designed for different purposes, and the specific product label should be consulted to confirm which type is being used.


Q: Does taking Araam with food help reduce the chance of side effects?

Patient instructions sometimes advise taking the tablets with food or milk. While taking it with food may slightly slow the rate of absorption, it is often advised to potentially help reduce stomach upset, which is a common side effect of NSAIDs.


Q: Can Araam cause heartburn, and what helps to manage it?

Yes, common side effects of the active ingredients can include gastrointestinal issues like heartburn or indigestion. Official labels do not typically provide direct management advice for minor symptoms, and consulting a healthcare professional is advised if symptoms persist or become severe.


Q: What signs might indicate a rare but serious skin reaction to Araam?

Official safety information reports a very rare risk of serious cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome. Signs that require immediate medical attention may include blistering, peeling, or a severe widespread rash on the skin, particularly if accompanied by a fever.


Q: Can Araam be taken with other medicines that contain Paracetamol or Acetaminophen?

Araam is a combination product that contains Paracetamol (Acetaminophen) as one of its active ingredients. Regulatory documents strongly caution against taking other products that also contain Paracetamol, as this can lead to exceeding the maximum daily dose and risking serious liver injury.


Q: Is it safe to consume alcohol while taking Araam?

The use of this medication with alcohol carries a potential risk. Patients with high daily alcohol consumption should discuss this with a healthcare professional, as heavy alcohol use may increase the risk of stomach bleeding and liver injury when combined with NSAIDs and Paracetamol.


Q: Does Araam affect the effectiveness of oral contraceptives?

Official information generally indicates that Diclofenac, the main NSAID component, does not affect the effectiveness of hormonal contraceptives like the combined or progestogen-only pill. However, severe vomiting or diarrhea caused by any medication can potentially affect how well the pill is absorbed.


Q: Is Araam suitable for use in children under 18?

Diclofenac is generally not recommended for use in children and adolescents under 18 years of age. Use in this age group is typically restricted unless specifically prescribed and dosed by a healthcare professional, as safety has not been established for many indications.


Q: Does Araam affect the ability to drive or operate heavy machinery?

Yes, official warnings advise caution. Because side effects like dizziness, drowsiness (somnolence), or blurred vision have been reported, it is generally advised to avoid activities that require high alertness if these symptoms are experienced.


Q: Does Araam have a risk of becoming habit-forming or causing dependence?

As a combination of an NSAID and Paracetamol, this medication is not classified as an addictive substance or a controlled drug. Therefore, it does not carry the risk of physical dependence or abuse that is associated with opioid or other controlled pain medicines.


Q: What should be done if a dose of Araam is accidentally missed?

Official instructions indicate that if a dose is missed, the patient should proceed with the next scheduled dose. It is crucial not to take a double dose to compensate for the missed one, and always maintain the required interval between doses.


Q: Can Araam be used to treat migraines or tension headaches?

Specific formulations of Diclofenac are indicated in official labeling for the acute treatment of migraine attacks. However, it may not be indicated for treating common tension headaches in all forms, so the specific product label should be reviewed.


Q: Is it normal to feel a dry mouth while taking Araam?

Dry mouth is listed in official adverse event reports as a reaction that has been occasionally reported with the use of Diclofenac. If this symptom becomes bothersome or severe, a healthcare professional should be consulted.


Q: Does Araam cause constipation or diarrhea, and how can these be managed?

Diarrhea is a commonly reported gastrointestinal side effect, and constipation has also been reported. While the official labels document these effects, they do not usually provide direct management advice, recommending consultation with a healthcare provider instead.


Q: Are there any particular foods or supplements that should be avoided when taking Araam?

Official warnings primarily focus on limiting or avoiding alcohol consumption. However, general caution is recommended regarding taking the medication with certain herbal remedies or supplements without professional guidance to prevent unforeseen interactions.


Q: Does Araam interfere with any common blood tests?

Yes, the components of Araam can affect certain blood test results. Diclofenac may cause changes in liver function tests, and high doses of Paracetamol may potentially affect blood clotting tests (PT/INR) in some cases.


Q: Can Araam be taken if a person has asthma or nasal polyps?

Official documents state that Araam (Diclofenac) is generally contraindicated in patients who have a history of asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other NSAIDs. This is because of the potential for a severe allergic reaction in people sensitive to NSAIDs.


Q: What is the recommendation regarding Araam for people with diabetes?

There is no official general contraindication for use in patients with diabetes. However, patients should note that high doses of Paracetamol can interfere with the readings of some Continuous Glucose Monitoring (CGM) systems, and this information should be reviewed with a healthcare professional.


Q: Are there any noticeable effects on sleep patterns when taking Araam?

Adverse effects related to the nervous system, such as drowsiness (somnolence) and insomnia (difficulty sleeping), have been reported in official documents for Diclofenac. Any significant change in sleep patterns should be reported to a healthcare provider.


Q: Is it possible for Araam to cause ringing or buzzing in the ears (tinnitus)?

Yes, ringing or buzzing in the ears, medically known as tinnitus, is listed as an adverse reaction that has been reported with the use of Diclofenac.


Q: Can Araam be taken by someone with an existing kidney or liver condition?

The drug is formally contraindicated in cases of severe kidney or liver failure. For existing mild-to-moderate impairment, caution and dose reduction are often required, and this population may require careful monitoring and may be at a higher risk for certain side effects.


Q: Is it necessary to take Araam at a fixed time each day?

While it is necessary to follow the prescribed frequency (e.g., three times daily) and maintain the minimum interval between doses, the specific time of day is generally flexible unless your doctor has given explicit instructions for a fixed schedule.


Q: Can Araam be used for pain after a minor surgery or dental procedure?

Yes, Diclofenac, an active ingredient in Araam, is generally indicated for managing acute pain, which includes pain that may be experienced following minor surgical or dental procedures.


Q: Can Araam cause any psychological side effects like confusion?

Official regulatory reports include psychological adverse effects such as anxiety, depression, and confusion that have been reported with the use of Diclofenac.


Q: Why is it important not to crush or chew Araam tablets?

Tablets, particularly those with special coatings or extended-release formulations, must be swallowed whole without crushing or chewing. This ensures that the medicine is released slowly and at the correct time in the body, maintaining its intended effect and minimizing risks.


Q: Does Araam interfere with female fertility or conception attempts?

Official warnings for NSAIDs indicate that Diclofenac may temporarily impair female fertility. This effect is generally considered reversible upon discontinuation of the medicine.


Q: Does Araam carry a warning about potential cardiovascular risks?

Yes, NSAIDs, including Diclofenac, carry a regulatory warning (a boxed warning in the US) regarding the risk of serious and potentially fatal cardiovascular thrombotic events. These can include heart attack (myocardial infarction) and stroke.


Q: How quickly can a person expect Araam to start working?

Official information for its components suggests that certain forms, such as Diclofenac Potassium, are designed for quicker initial absorption than others. However, the exact time of onset for pain relief can vary by individual and formulation.


Q: Is feeling dizzy or drowsy a common side effect when starting Araam?

Dizziness is commonly reported in official safety documents. Drowsiness (somnolence) is reported less frequently. If either symptom occurs, it is important to exercise caution and avoid activities that require alertness.


Q: Is Araam known to interact with common blood pressure medications?

Regulatory documents list certain calcium channel blockers, which are used for blood pressure, as moderate inhibitors of Araam’s metabolism. Co-administration may require a mandatory maximum daily dose limit for Araam to manage potential increased exposure.


Q: Does Araam interact with common blood thinning medications like warfarin?

Yes, a significant interaction risk exists with anticoagulants like warfarin. NSAIDs can increase the risk of serious bleeding events, and this combination typically requires close monitoring of blood clotting parameters.


Q: What is the general advice for pregnant or breastfeeding women regarding Araam?

Use of Araam is generally restricted during the late stages of pregnancy due to potential risks to the fetus. The official eligibility status and constraints for use during other stages of pregnancy or while breastfeeding are not always fully defined in public regulatory records and should be discussed with a healthcare professional.


Q: Is Araam generally safe for elderly patients?

Regulatory guidance advises that caution should be used and the lowest effective dose should be administered to elderly patients. This population may require careful monitoring and may be at a higher risk for certain side effects.


Q: What is the typical duration of pain relief provided by one dose of Araam?

Official administration guidelines focus on the frequency and interval of dosing, rather than a specific duration of pain relief. Patients are advised to follow the prescribed frequency and not exceed the minimum time between doses.

How should Araam be stored and disposed of?

Storage Conditions

Araam must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The product must be kept in its original, tightly closed container and protected from excessive heat, moisture, and light. It is a mandatory requirement to keep from freezing and to ensure the medicine is stored out of the reach and sight of children at all times.

Disposal Instructions

Disposal of unused or expired Araam should prioritize official community drug take-back programs. If a take-back program is unavailable and the medication is not on the regulatory flush list, it may be disposed of in the household trash. This requires mixing the medicine with an undesirable substance (such as dirt) and placing the mixture in a sealed container before discarding. Do not flush the medication down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Araam found in:

A-Z Index: